CDEK
← Mechanisms of action

IL3RA

SINGLE PROTEINHomo sapiens
Preferred name: Interleukin-3 receptor subunit alpha ChEMBL ↗

Linked proteins

Drugs acting on this target (43)

Active Pharmaceutical Ingredient Mechanism Type ▲ Approval Status API Type Mechanism of Action
il-3 (Muplestim)AgonistexperimentalRecombinant proteinIL3RA agonist
sprx002AntagonistexperimentalCell therapyIL3RA antagonist
tagraxofusp-erzs (elzonris)AntagonistapprovedRecombinant proteinIL3RA antagonist
afm28Binding agentexperimentalmAbIL3RA binding agent
FlotetuzumabBinding agentexperimentalmAbInterleukin-3 receptor subunit alpha binding agent
imgn632Binding agentexperimentalmAbInterleukin-3 receptor subunit alpha binding agent
mgd024Binding agentexperimentalmAbIL3RA binding agent
tagraxofusp-erzs (elzonris)Binding agentapprovedRecombinant proteinInterleukin-3 receptor subunit alpha binding agent
talacotuzumabBinding agentexperimentalmAbInterleukin-3 receptor subunit alpha binding agent
4scar123Immunity, passiveexperimentalCell therapyIL3RA immunity, passive
allo-revcar01-tImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
anti tim-3/cd123 car-t cell therapyImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
autologous anti-cd 123 car tcr/4-1bb-expressing t-lymphocytesImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
cd123 car-t cellsImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
cd123 cll-1 dual-target car-t cellsImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
cd123-car-nk cellsImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
cd123-cd33 ccar t cellsImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
cd123/cll1 car-t cellsImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
ci-135 car-t cellsImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
donor-derived cd123-cd16 bispecific antibody-modified nk cellsImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
il13rα2 car-tImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
il3 car-t cellsImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
jd123Immunity, passiveexperimentalCell therapyIL3RA immunity, passive
mb-102Immunity, passiveexperimentalCell therapyIL3RA immunity, passive
r-tm123Immunity, passiveexperimentalCell therapyIL3RA immunity, passive
third-generation anti-cd123 car-t cellsImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
ucart123Immunity, passiveexperimentalCell therapyIL3RA immunity, passive
unicar02-tImmunity, passiveexperimentalCell therapyIL3RA immunity, passive
apvo436InhibitorexperimentalmAbIL3RA inhibitor
azd9829InhibitorexperimentalmAbIL3RA inhibitor
byon4413InhibitorexperimentalmAbIL3RA inhibitor
csl-360InhibitorexperimentalmAbIL3RA inhibitor
csl362InhibitorexperimentalmAbIL3RA inhibitor
FlotetuzumabInhibitorexperimentalmAbIL3RA inhibitor
imgn632InhibitorexperimentalmAbIL3RA inhibitor
jnj-63709178InhibitorexperimentalmAbIL3RA inhibitor
khk2823InhibitorexperimentalmAbIL3RA inhibitor
mp0533InhibitorexperimentalRecombinant proteinIL3RA inhibitor
sar440234InhibitorexperimentalmAbIL3RA inhibitor
sgn-cd123aInhibitorexperimentalmAbIL3RA inhibitor
talacotuzumabInhibitorexperimentalmAbIL3RA inhibitor
vip943InhibitorexperimentalmAbIL3RA inhibitor
xmab14045InhibitorexperimentalmAbIL3RA inhibitor